Ademi LLP is investigating Apogee Therapeutics for possible breaches of fiduciary duty in its recently announced transaction with CRH. Apogee shareholders will receive $135.11 per share in cash, valuing Apogee at approximately $10.9 billion in total equity value. The investigation focuses on whether the Apogee board of directors is fulfilling its fiduciary duties to all shareholders, particularly given that insiders will receive substantial benefits as part of change of control arrangements. The transaction agreement imposes a significant penalty if Apogee accepts a competing bid, which the firm says unreasonably limits competing transactions.
Apogee Therapeutics, Inc. Common StockInvestigation into fiduciary duties and deal terms may reduce shareholder value or block the acquisition.